Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world settingChristos Chouaid, Jason Agulnik, Erdem Goker, et al.
Annals of Nuclear Medicine|October 18, 2020
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancerRomain-David Seban, Jean-Baptiste Assie, Etienne Giroux-Leprieur, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|January 22, 2011
Effects of polycythemia on systemic endothelial function in chronic hypoxic lung diseaseLaurent Boyer, Vicky Chaar, Gabriel Pelle, et al.
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Circulation Research|July 2, 2011
Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung diseaseHibo Noureddine, Guillaume Gary-Bobo, Marco Alifano, et al.
Cancers|December 5, 2020
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019Jean-Bernard Auliac, Sophie Bayle, Pascal Do, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON studyChristos Chouaid, Lise Bosquet, Craig Knott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2015
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01Pierre Fournel, Alain Vergnenégre, Gilles Robinet, et al.
Cancers|August 14, 2020
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line PembrolizumabRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
Clinical Lung Cancer|July 26, 2025
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter StudyLina Atlagh, Anne-Claire Toublanc, Benoit Roch, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world settingChristos Chouaid, Jason Agulnik, Erdem Goker, et al.
Annals of Nuclear Medicine|October 18, 2020
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancerRomain-David Seban, Jean-Baptiste Assie, Etienne Giroux-Leprieur, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|January 22, 2011
Effects of polycythemia on systemic endothelial function in chronic hypoxic lung diseaseLaurent Boyer, Vicky Chaar, Gabriel Pelle, et al.
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Circulation Research|July 2, 2011
Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung diseaseHibo Noureddine, Guillaume Gary-Bobo, Marco Alifano, et al.
Cancers|December 5, 2020
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019Jean-Bernard Auliac, Sophie Bayle, Pascal Do, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON studyChristos Chouaid, Lise Bosquet, Craig Knott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2015
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01Pierre Fournel, Alain Vergnenégre, Gilles Robinet, et al.
Cancers|August 14, 2020
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line PembrolizumabRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
Clinical Lung Cancer|July 26, 2025
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter StudyLina Atlagh, Anne-Claire Toublanc, Benoit Roch, et al.
Pageof 21